Other languages Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
44.64 ^USD	+7.83%		+7.70%	-6.65%

Jun. 12	Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	MT
Jun. 12	Ultragenyx Pharmaceutical Launches Equity Offering	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	Jun. 12
Ultragenyx Pharmaceutical Launches Equity Offering	Jun. 12
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 12
Sector Update: Health Care	Jun. 12
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	Jun. 12
Sector Update: Health Care Stocks Rise Premarket Wednesday	Jun. 12
Sector Update: Health Care	Jun. 12
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	Jun. 12
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	Jun. 12
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia	May. 30
Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)	May. 28
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	May. 14
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	May. 02
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta (OI)	Apr. 30
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	Mar. 12
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	Feb. 15
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Other languages

Filters